Drugs / Sho-saiko-to
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00590564 | Oct 2002 → Feb 2011 | chronic hepatitis C virus infection | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00633230 Comparator | — | hepatitis C virus infection | University of Virginia | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sho-saiko-to | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00633230 ↗ |
| Action | Inhibit | “by inhibition of lipid peroxidation in hepatocytes and stellate cells” NCT00590564 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Sho-saiko-to is an herbal medicine that has been used for many years in Asia to treat liver disease.” NCT00590564 ↗ |
| Route | Oral | “by mouth” NCT00590564 ↗ |